[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367043-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367043-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","efficacy-of-cbpp300-dual-inhibitors-against-derepression-of-kremen2-in-cbaf-deficient-cancers","Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers","","SWI/SNF chromatin remodeling splits into cBAF, PBAF, and ncBAF, and cancers frequently carry abnormalities in SWI/SNF constituent genes such as SMARCB1, SMARCA4, SMARCA2, and SS18. CBP/p300 dual inhibition triggers synthetic lethality in cBAF-deficient cancers, including SMARCA4/SMARCA2-deficient and SS18–SSX fusion types. Mechanistically, dual inhibition represses KREMEN2 transcription via concurrent CBP/p300 blockade, then activates apoptosis through KREMEN1. Xenografts derived from sensitive cells show suppressed growth due to KREMEN2 repression and apoptosis induction.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-of-cbpp300-dual-inhibitors-against-derepression-of-kremen2-in-cbaf-deficient-cancers/367043/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-of-cbpp300-dual-inhibitors-against-derepression-of-kremen2-in-cbaf-deficient-cancers/367043.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic strategy evaluated in the study?","Question",{"text":63,"@type":64},"The study evaluates CBP/p300 dual inhibitors as a treatment approach for cancers deficient in the cBAF subcomplex of the SWI/SNF chromatin remodeling complex.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cancer models show sensitivity to CBP/p300 dual inhibitors?",{"text":68,"@type":64},"Sensitivity is demonstrated in cBAF-deficient cancers, including SMARCA4/SMARCA2-deficient cancers and SS18–SSX fusion cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"How does KREMEN2 repression contribute to the observed cell death?",{"text":72,"@type":64},"Simultaneous inhibition of CBP/p300 downregulates KREMEN2 transcription, which leads to apoptosis induction via KREMEN1.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367043,1790362292,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-24-0484](https://doi.org/10.1158/2767-9764.CRC-24-0484)  OPEN ACCESS  \nEfficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers  \nMariko Sasaki1, Daiki Kato2, Hiroshi Yoshida3, Takafumi Shimizu2, and Hideaki Ogiwara1  \n􀀶  \nABSTRACT  \nThe SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex is divided into three subcomplexes: cBAF, PBAF, and ncBAF. Constituent genes (e.g., SMARCB1, SMARCA4, SMARCA2, and SS18) of the SWI/SNF complex often harbor genetic abnormalities in various cancers. Previously, we found that histone acetyltransferases CBP/p300 dual inhibitors could be promising treatments for SMARCB1-deficient cancers. We show that treatment with CBP/p300 dual inhibitors causes synthetic lethality in cBAF-deficient cancers such as SMARCA4/ SMARCA2-deficient and SS18–SSX fusion cancers. Given the sensitivity to CBP/p300 dual inhibitors and their commonality with SWI/SNF subcomplexes containing each subunit, CBP/p300 dual inhibitors could be promising treatments for cancers harboring abnormalities in constituent genes included in the entire cBAF subcomplex. Because SMARCA4/SMARCA2-deficient and SS18–SSX fusion cancer cells depend on transcriptional upregulation of KREMEN2 due to SMARCA4/ SMARCA2 deficiency and SS18–SSX fusion, we clarified that synthetic  \nlethality is induced by repressing expression of KREMEN2 by simultaneous inhibition of CBP/p300. In addition, simultaneous inhibition of CBP/ p300 led to transcriptional downregulation of KREMEN2, followed by apoptosis induction via KREMEN1. Furthermore, treatment with CBP/p300 dual inhibitor suppressed the growth of xenografts derived from SMARCA4/ SMARCA2-deficient and SS18–SSX fusion cancer cells, resulting from repression of KREMEN2 and induction of apoptosis. Thus, CBP/p300 dual inhibitors could be promising for SMARCA4/SMARCA2-deficient lung cancer and SS18–SSX fusion synovial sarcoma, which are entirely deficient in the cBAF complex.  \nSignificance: In this study, we clarified that the cBAF subcomplex is deficient in the SWI/SNF complex, resulting in dependency on the CBP/ p300 paralog pair. Simultaneous inhibitors of the CBP/p300 paralog pair show promise for cBAF-deficient lung cancer, as well as rare cancers such as malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas.  \nIntroduction  \nCancer genomic medicine, a form of cancer treatment that aims to address genetic mutations within cancerous cells specifically, is expected to advance through improvements in multigene panel testing ( 1) . Cancer genomic medicine is utilized primarily for cancers exhibiting gain-of-function mutations in oncogenes (2) . Although there are loss-of-function (LOF) mutations in tumor suppressor genes, these genes cannot be targeted for therapy. Synthetic lethality refers to cell death triggered by simultaneous inhibition of two genes rather than just one gene (3) . Currently, synthetic lethal agents  \n1Division of Cancer Therapeutics, National Cancer Center Research Institute, Tokyo, Japan. 2Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan. 3Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan. Corresponding Author: Hideaki Ogiwara, Division of Cancer Therapeutics, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.  \nE-mail: [hogiwara@ncc.go.jp](hogiwara@ncc.go.jp)  \ndoi: 10.1158/2767-9764.CRC-24-0484  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2024 The Authors; Published by the American Association for Cancer Research  \nthat focus on a synthetic lethal factor in cancers displaying LOF mutations are a treatment option for cancer.  \nMutations in genes that encode subunits of the SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeling complex are found in around 20% of all cancer cases (4, 5) . This ","cbCaidNk17XC1CfO","https://ap.wps.com/l/cbCaidNk17XC1CfO","pdf",7618293,15,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What is the main therapeutic strategy evaluated in the study?\",\"answer\":\"The study evaluates CBP/p300 dual inhibitors as a treatment approach for cancers deficient in the cBAF subcomplex of the SWI/SNF chromatin remodeling complex.\"},{\"question\":\"Which cancer models show sensitivity to CBP/p300 dual inhibitors?\",\"answer\":\"Sensitivity is demonstrated in cBAF-deficient cancers, including SMARCA4/SMARCA2-deficient cancers and SS18–SSX fusion cancers.\"},{\"question\":\"How does KREMEN2 repression contribute to the observed cell death?\",\"answer\":\"Simultaneous inhibition of CBP/p300 downregulates KREMEN2 transcription, which leads to apoptosis induction via KREMEN1.\"}]","Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers | PDF",1790168985,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c193e45b7b1b789f8970494b3d19f7ef.webp",983,1263,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5c9b174eb147884e2fe37c0f462086d.webp",982,1262,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c70dde2390e194d2635a880fe12d1b5c.webp",981,1261,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1199998de85972a92a176a849d2fd4d8.webp",980,1259]